Skip to Main Content

Opinions+

Perspectives on issues affecting biopharma and health care.

Latest

First Opinion David Balto

STAT Plus: Pharmacy benefits managers should be worried

First Opinion Sadiq Y. Patel

STAT Plus: How AI can help bring better care to Medicaid patients

Opinions+ Caleb Appleton

STAT Plus: Is this the beginning of the AI-in-drug-discovery era, or the beginning of the end?

First Opinion David Balto

STAT Plus: Don’t expect Novo-Catalent merger investigation to fizzle out under the new Trump administration

First Opinion Neil Kelleher and Rohan Ganesh

STAT Plus: The U.S. is at risk of losing the proteomics race to China

First Opinion Amit Agrawal

STAT Plus: Precision medicine can’t fulfill its promise without better diagnostics

First Opinion Torie Bosch

STAT Plus: Four leading biopharma executives weigh the 2024 election

First Opinion Fritz Bittenbender

STAT Plus: Genentech executive Fritz Bittenbender: Beware political soundbites

All Coverage

Opinions+ Emil D. Kakkis

STAT Plus: Traditional randomized trials don’t work for ultra-rare diseases like Barth syndrome

First Opinion Cheri Banks

STAT Plus: Five things FDA ad comm members want

advertisement

First Opinion Jack Hooper

STAT Plus: What does the presidential election mean for ICHRA and the health insurance market?

First Opinion Kendalle Burlin O’Connell

STAT Plus: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma

First Opinion Sarah Emond

STAT Plus: What the newly released Medicare prices for 10 drugs do and don’t tell us

Opinions+ Priya Baraniak

STAT Plus: Cell donors are essential for new therapies. They need to be taken care of

Opinions+ Bruce Leuchter

STAT Plus: Private equity and neuroscience: a novel approach to developing new treatments for neurological disorders

Opinions+ Ashu Singhal and Sajith Wickramasekara

STAT Plus: Could billions of dollars in AI funding lead to the same number of new drugs?

Opinions+ Hope Meely

STAT Plus: Unmasking the ‘centricity’ illusion in clinical trials

Opinions+ Lee A. Fleisher and Matthew A. Fleisher

STAT Plus: Use evidence to support early coverage of gene therapy after accelerated approval

Opinions+ Wendy Cheng

STAT Plus: How AI can help satisfy FDA’s drug, device diversity requirements

Opinions+ Kyle H. Sheetz and Robert M. Wachter

STAT Plus: Medical devices makers are trying to take a page from Uber’s playbook

First Opinion Amit Etkin

STAT Plus: It’s time to rethink everything about our approach to psychiatric drug development

First Opinion Juliana M. Reed

STAT Plus: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

First Opinion Dan Troy

STAT Plus: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

Opinions+ John Whyte

STAT Plus: Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit

First Opinion Christopher Palatucci

STAT Plus: The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs

First Opinion Shirley Leung

STAT Plus: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker

First Opinion Peter Shen

STAT Plus: Health care AI requires a new Hippocratic oath

First Opinion Jeremy L. Shane

STAT Plus: A bold approach to pay for weight loss drugs for everyone who needs them

Opinions+ Paul Jones

STAT Plus: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint